Impact of therapeutic strategies on the prognosis of Candidemia in the ICU

Critical Care Medicine

Volumn 42, Issue 6, 2014, Pages 1423-1432

  Puig Asensio, Mireia ^a   Pemán, Javier ^b   Zaragoza, Rafael ^c   Garnacho Montero, José ^d   Martín Mazuelos, Estrella ^e   Cuenca Estrella, Manuel ^f   Almirante, Benito ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antifungal agents; candidiasis; epidemiology; intensive care units; mortality; treatment outcome

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; PYRROLE;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CATHETER REMOVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; FUNGUS ISOLATION; HUMAN; INDWELLING CATHETER; INTENSIVE CARE UNIT; KLUYVEROMYCES MARXIANUS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; SPAIN; TREATMENT OUTCOME;

AGED; ANTIFUNGAL AGENTS; APACHE; CANDIDA; CANDIDEMIA; CENTRAL VENOUS CATHETERS; DRUG RESISTANCE, FUNGAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POPULATION SURVEILLANCE; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; SPAIN;

EID: 84901313627     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000221     Document Type: Article

References (46)

1. Vincent JL,Rello J,Marshall J,et al, EPIC II Group of Investigators: International study of the prevalence and outcomes of infection in intens ive care units. JAMA,2009,302, 2323-2329.
2. Suetens C, Morales I, Savey A, et al: European surveillance of ICU-acquired infections (HELICS-ICU): Methods and main results. J Hosp Infect 2007; 65(Suppl 2):171-173
3. Montagna MT, Caggiano G, Lovero G, et al: Epidemiology of invasive fungal infections in the intensive care unit: Results of a multicenter Italian survey (AURORA Project). Infec tion 2013; 41:645-653
4. Wisplinghoff H, Bischoff T, Tallent SM, et al: Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-317
5. Kett DH, Azoulay E, Echeverria PM, et al; Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators: Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of in fection in intensive care unit study. Crit Care Med 2011; 39:665-670
6. Marriott DJ, Playford EG, Chen S, et al; Australian Candidaemia Study: Determinants of mortality in non-neutropenic ICU patients with candidaemia. Crit Care 2009; 13:R115
7. Gonzalez de Molina FJ, Leon C, Ruiz-Santana S, et al: Assessment of candidemia-attributable mortality in critically ill patients using propensity score matching analysis. Crit Care 2012; 16:R105
8. Chow JK, Golan Y, Ruthazer R, et al: Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intens ive care unit. Clin Infect Dis 2008; 46:1206-1213
9. Bassetti M, Ansaldi F, Nicolini L, et al: Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J Antimicrob Chemother 2009; 64:625-629
10. Leroy O, Gangneux JP, Montravers P, et al; AmarCand Study Group: Epidemiology, management, and risk factors for death of invasive Candida infections in critical care : A multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009; 37:1612-1618
11. Bougnoux ME, Kac G, Aegerter P, et al; CandiRea Study Group: Candidemia an d candiduria in critically ill patients admitted to intensive care units in France: Incidence, molecular diversity, management and outcome. Intensive Care Med 2008; 34:292-299
12. Tortorano AM, Dho G, Prigitan o A, et al; ECMM-FIMUA Study Group: Invasive fungal infections in the intensive care unit: A multicentre, prospective, observational study in Italy (2006 -2008). Mycoses 2012; 55:73-79
13. Bassetti M, Righi E, Costa A, et al: Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006; 6:21
14. Guo F, Yang Y, Kang Y, et al; China-SCAN Team: Invasive c andidiasis in intensive care units in China: A multicentre prospective observational study. J Antimicrob Chemother 2013; 68:1660-1668
15. Labelle AJ, Micek ST, Roubinian N, et al: Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008; 36:2967-2972
16. Garnacho-Montero J, Dí az-Martín A, García-Cabrera E, et al: Impact on hospital mort ality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections. J Antimicrob Chemother 2013; 68:206-213
17. Grim SA, Berger K, Teng C, et al: Timing of suscepti bility-based antifungal drug administration in patients with Candida bloodstream infection: Correlation with outcomes. J Antimicrob Chemother 2012; 67:707-714
18. Andes DR, Safdar N, Baddley JW, et al; Mycoses Study Group: Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: A patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54:1110-1122
19. Blot SI, Vandewoude KH, Hoste EA, et al: Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113:480-485
20. Puig-Asensio M, Padilla B, Garnacho-Montero M, et al: Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: A population-based surveillance in Spain. Clin Microbiol Inf ect 2013 Aug
21. [Epub ahead of print] Mermel LA, Allon M, Bouza E, et al: Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection , 2009 Update by the Infectious Diseases Society of America , Clin Infect Dis, 2009,49, 1-45.
22. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
23. Levy MM, Fink MP, Marshall JC, et al; International Sepsis Definitions Conference: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intens ive Care Med 2003; 29:530-538
24. The European Committee on Antimicrobial Susceptibility testing-EUCAST: Clinical breakpoints-Fungi. Table v 6.1. Available at: http://www.eucast.org/ clinical-breakpoints/. Accessed May 1, 2013
25. Tavanti A, Hensgens LA, Ghelardi E, et al: Genotyping of Candida orthopsilosis clinical isolates by amplification fragment length polymorphism reveals genetic diversity among independ ent isolates and strain maintenance within patients. J Clin Microbiol 2007; 45:1455-1462
26. Tavanti A, Davidson AD, Gow NA, et al: Candida orthopsilosis and Candida metapsilosis spp. nov. to rep lace Candida parapsilosis groups II and III. J Clin Microbiol 2005; 43:284-292
27. Alcoba-Fló rez J, del Pilar Arévalo M, González- Paredes FJ, et al: PCR protocol for specific identification of Ca ndida nivariensis, a recently described pathogenic yeast. J Clin Microbiol 2005; 43:6194-6196
28. Rodriguez-Tudela JL, Arendrup MC, Barchiesi F, et al: EUCAST definitive document EDef 7.1: Method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008; 14:398-405
29. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, et al; EUCAST -AFST: EUCAST technical note on the EUCAST definitive document EDef 7.2: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 ( EUCAST-AFST). Clin Microbiol Infect 2012; 18:E246-E247
30. Almirante B, Rodrí guez D, Park BJ, et al; Barcelona Candidemia Project Study Group: Epidemiology and predictors of mortality in cases of Candida bloodstream infection: Results from population-based surve illance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43:1829-1835
31. Pemá n J, Cantón E, Quindós G, et al; FUNGEMYCA Study Group: Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother 2012; 67:1181-1187
32. Almirante B, Rodrí guez D, Cuenca-Estrella M, et al: Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: Case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin M icrobiol 2006; 44:1681-1685
33. Pappas PG, Kauffman CA, Andes D, et al; Infectious Diseases Society of America: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-535
34. Lortholary O, Desnos-Ollivier M, Sitbon K, et al; French Mycosis Study Group: Recent exposure to caspofungin or fluconazo le influences the epidemiology of candidemia: A prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011; 55:532-538
35. Forrest GN, Weekes E, Johnson JK: Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008; 56:126-129
36. Pai MP, Turpin RS, Garey KW: Association of fluconazole area under the concentration-time curve/MIC and d ose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007; 51:35-39
37. Cornely OA, Bassetti M, Calandra T, et al; ESCMID Fungal Infection Study Group: ESCMID*guideline for the diagnosis and management of Candida diseases 2012: Non-neutropenic adult patients. Cflin Microbiol Infect 2012; 18(Suppl 7):19-37
38. Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, et al; French Mycoses Study Group: Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg Infect Dis 2012; 18:86-90
39. Alexander BD, Johnson MD, Pfeiffer CD, et al: Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Inf ect Dis 2013; 56:1724-1732
40. Kollef M, Micek S, Hampton N, et al: Septic shock attributed to Candida infection: Importance of empiric therapy and source control. Clin Infect Dis 2012; 54:1739-1746
41. Nucci M, Anaissie E, Betts RF, et al: Early removal of central venous catheter in patients with candidemia does not improve outcome: Analysis of 842 patients from 2 randomized clinical trial s. Clin Infect Dis 2010; 51:295-303
42. Morrell M, Fraser VJ, Kollef MH: Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: A potentia l risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640-3645
43. Hsu DI, Nguyen M, Nguyen L, et al: A multicentre study to evaluate the impact of timing of caspofungin adm inistration on outcomes of invasive candidiasis in non-immunocompromised adult patients. J Antimicrob Chemother 2010; 65:1765-1770
44. Parkins MD, Sabuda DM, Elsayed S, et al: Adequacy of empiri cal antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007; 60:613-618
45. Garey KW, Rege M, Pai MP, et al: Time to initiati on of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis 2006; 43:25-31
46. Leó n C, Ruiz-Santana S, Saavedra P, et al; Cava Study Group: Usefulness of the " Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: A prospective multicenter stu dy. Crit Care Med 2009; 37:1624-1633